In this episode, we dove deep into the world of proteomics, discussing how data science is being used to analyze the vast amounts of protein data generated by this cutting-edge field.
We are joined by leading experts in the field of data science and proteomics, Lennart Martens, professor at Ghent University and head of the Computational Omics and Systems Biology group, and Gerben Menschaert, Associate Professor at Ghent University and CSO of OHMX.bio, have both have made significant contributions to the proteomics field through their research, who share their insights on the latest trends and technologies, as well as the challenges and opportunities that lie ahead.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
